سعر لوبرون ديبوت ساندوز 1 شهر 1 سرنجة 2022

Leupro-sandoz 1-month-depot 1 syringe: leuprorelin 1-month depot, one syringe (Sandoz/Novartis); GnRH analogue. Strength and exact dosage form are not stated by the Egyptian sources.

• US LUPRON DEPOT 7.5 mg (1-month): most common (>10%) general pain, hot flashes/sweats, gastrointestinal disorders, oedema, respiratory disorders and urinary disorders.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to GnRH, GnRH agonists or any excipient (anaphylactic reactions to GnRH agonists have been reported).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Tumour flare: testosterone rises about 50% above baseline in the first weeks, which may worsen bone pain, neuropathy, haematuria or ureteral obstruction; spinal cord compression, which may contribute to paralysis, can occur. Monitor for worsening prostate cancer symptoms in the first weeks.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Metabolic changes (hyperglycaemia, diabetes, hyperlipidaemia, fatty liver disease) and increased risk of myocardial infarction, sudden cardiac death and stroke have been reported with GnRH agonists in men.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Androgen deprivation therapy may prolong the QT/QTc interval; correct electrolytes and consider ECG monitoring, especially with congenital long QT, heart failure or QT-prolonging drugs.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Convulsions and severe cutaneous adverse reactions (SJS/TEN, DRESS, AGEP) have been reported; interrupt treatment if a severe skin reaction is suspected.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Diagnostic tests of pituitary-gonadal functionResults may be affected during treatment and for up to 3 months after stopping because of pituitary-gonadal suppression.DailyMed (U.S. National Library of Medicine)

• May cause fetal harm based on animal findings and mechanism of action; no data in pregnant women.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Monitor tumour-flare symptoms in the first weeks, blood glucose/HbA1c and lipids, cardiovascular signs, and consider periodic ECG and electrolytes.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Leuprorelin: GnRH analogue: initial rise in gonadotrophins, then pituitary desensitisation/down-regulation with suppression of sex hormones (Egyptian directory pharmacology text).